Belite Bio Inc

BLTE

Healthcare|Biotechnology|USA

$149.25

-3.91 (-2.55%)

Tangible Book

$19.85

Clinical Trials (7)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06388083 A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease	STGD1, Stargardt Disease 1	P2P3	Active	60	RCT, Double-blind	Tinlarebant, Placebo
NCT05949593 Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy	Geographic Atrophy	P3	Active	429	RCT, Double-blind	Tinlarebant, Placebo
NCT05244304 Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease	Stargardt Disease 1	P3	Completed	104	RCT, Double-blind	Tinlarebant, Placebo
NCT05266014 This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease	Stargardt Disease	P1P2	Completed	13	Open-label	tinlarebant
NCT04005807 Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults	Healthy Volunteers	P1	Completed	40	RCT, Double-blind	BPN-14967, Placebo
NCT05667688 Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85	Healthy Volunteer, Dry Age-related Macular Degeneration	P1	Completed	15	Open-label	Tinlarebant (LBS-008)
NCT03735810 Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses	Healthy Volunteer	P1	Completed	71	RCT, Double-blind	LBS-008, Placebos